Loading stock data…
NeoGenomics, Inc. (NEO)
$17.56+0.18 (+1.04%)
Market ClosedLast close Sep 8
NeoGenomics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NeoGenomics, Inc. in the Healthcare sector is trading at $17.56 with a market capitalization of $2.0B. Wall Street consensus targets $19.72 (9 analysts), implying a +12.3% move over the next 12 months. The stock is currently near its 52-week high of $19.76, remaining 50.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $201.66M↑ | $186.67M↓ | $190.17M↑ | $187.80M↑ | $181.33M |
| Gross Profit | $91.88M↑ | $80.86M↓ | $83.34M↑ | $80.45M↑ | $77.26M |
| Operating Income | -$9.77M↑ | -$18.24M↓ | -$12.79M↑ | -$19.93M↑ | -$27.59M |
| Net Income | $2.24M↑ | -$17.11M↓ | -$9.88M↑ | -$27.13M↑ | -$45.09M |
Peer Comparison
JNJUNHPFE
Fundamentals
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical compani...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.00B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.73
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.60%
Volume
Today's trading volume
1.15M
Recent News
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
NeoGenomics Stock Just Turned Its First Profit, Creating an Optimal Entry Point
NeoGenomics (NEO) is a leading cancer genetics diagnostics lab. Its stock recently hit a new 2-year high. Shares are up more than 170% over the past 52 weeks. NEO maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is predominantly bullish, with consensus price targets up to $35 and...
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
Earnings, drug development, and healthcare reimbursement fueled the stock rallies.
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Unprofitable Stocks Walking a Fine Line
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.